News & Events

The Pharmabiotic Research Institute, as a partner of the Human Microbiome Action Consortium, is pleased to announce the publication of the paper, "State of the art and the future of microbiome-based biomarkers: a multidisciplinary Delphi...

Last month over 160 attendees joined together in Lille, France for the 9th annual Pharmabiotics Conference & Partnering event organized by PRI and I-Squared Communications. The 2024 edition focused on the theme of ‘An Evolving Regulatory...

Effective from 24 January 2024, Céline Druart has been appointed and will assume the role of PRI's new Executive Director.  After 13 years with the PRI, Dr. Magali Cordaillat-Simmons will resign from her position as PRI's Executive Director and...

The Pharmabiotics Conference Advisory Committee with the PRI Team and I-Squared Media are pleased to announce the upcoming 9th edition of the annual Pharmabiotics Conference & Partnering Event, 12-14 March, in Lille. This year’s theme, ‘An...

Next year PRI Microbiome Project Manager Céline Druart (PhD) will present at Hanson Wade's Microbiome Movement Drug Development Europe 2024 event. Her presentation is titled "European Regulatory Developments: Uncovering the New SoHo Regulation...

All PRI Members are invited to attend the annual Member Event - 7 November 2023. The Pharmabiotic Research Institute (PRI) is hosting its annual General Assembly & Member Event on 7 November 2023, in Ghent (Belgium). This Members-only meeting...

Last week PRI Executive Director Magali Cordaillat-Simmons (PhD) was an invited expert at ISAPP's annual meeting organized in Denver, Colorado. The International Scientific Association for Probiotics and Prebiotics (ISAPP) is "the international...

The Delphi Survey on finding a consensus around the development and validation of microbiome-based biomarkers has launched its second round (of two). This second and final round will remain open until the end of the day on June 6th. The second...

In June 2021, the European Pharmacopeia Commission (EDC) chose to embark upon the drafting of a new general chapter on phage therapy active substances and medicinal products for both human and veterinary use. The Bacteriophages Working Party was...

UPDATE (07/04/23) The Delphi Survey on finding a consensus around the development and validation of microbiome-based biomarkers is almost closed! The Survey platform will be open to accept submissions until 10 April. Once the platform closes, the...

Last week over 220 attendees joined together in Lyon, France for the 8th annual Pharmabiotics Conference & Partnering event. The 2023 edition focused on the main theme of ‘The Future of Microbiome-based Medicinal Products’, and brought together...

The PRI is pleased to host the 8th annual 2023 Pharmabiotics Conference & Partnering Event - returning to Lyon, France, at the Espace Tete d'Or Conference Center.   We are particularly proud of our program content this year, as we have...

This week PRI Microbiome Project Manager Céline Druart (PhD) will speak at Hanson Wade's Microbiome Movement Drug Development Europe event. Her presentation is titled, "Exploring the EU Proposal for a new SoHO Regulation and the Impact on...

The EDQM (European Directorate for the Quality of Medicines & Healthcare) has released the 5th version of the Guide to the quality and safety of tissues and cells for human application on 15 December 2022. This updated version results from an...

The PRI is pleased to announce Dr. Sandrine Claus has been elected Association President (effective 9 January 2023). As President, Sandrine will lead the Executive Committee and Board of Directors within the Association. Since the last update to...

All PRI Members are invited to attend our first in-person Member Event since 2019! The Pharmabiotic Research Institute (PRI) is hosting its annual General Assembly & Member Event on 1 December 2022, in Rotterdam (NL). This Members-only meeting...

On 14 July 2022 the European Commission published a draft proposal of its revision to the Blood Tissues and Cells (BTC) legislative framework. Following the announcement of the revision to the BTC legislation in 2019, it became apparent that this...

The microbiome field is suffering from limited reproducibility and comparability between studies, especially in large human cohorts. This lack of reproducibility and comparability is a major hurdle in the emergence of microbiome-based biomarkers....

On 13 June 2022 the EU-Innovation Network (jointly coordinated by the European Medicines Agency - EMA, and the Heads of Medicines Agencies - HMA) published a Horizon Scanning Report on Faecal Microbiota Transplantation. The report describes the use...

Following our announcement in February that we were recruiting a new member to the PRI Staff, we are pleased to announce that Dr. Julie Rodriguez (PhD) accepted to join the PRI as our new OMICS Project Manager. Julie Rodriguez obtained her PhD...

The Pharmabiotics 2022 Conference & Partnering Event was held on 20-21 April 2022 in Lyon, France. Nearly 200 delegates from industry and academia joined together to discuss a range of topics focusing on microbiome regulatory science,...

The PRI has been invited to join as a core partner the Human Microbiome Action consortium (https://humanmicrobiomeaction.eu/). As Europe’s Microbiome Regulatory Science expertise center, we are co-leading a transversal work package on Ethics &...